Traders assign a 91% probability against a new COVID variant of concern before 2027 because SARS-CoV-2 continues to evolve through Omicron sub-lineages without meeting the strict criteria for VOC designation, such as major shifts in transmissibility, severity, or immune escape. As of June 2026, organizations like ECDC report no active variants of concern, with strains like NB.1.8.1, XFG, and BA.3.2 classified only as variants under monitoring due to limited evidence of heightened public health impact. Recent surveillance through early 2026 shows BA.3.2 detections rising modestly in parts of Europe and the US via wastewater and traveler data, yet overall case severity and hospitalization trends remain stable and comparable to prior years. This sustained low-risk profile, backed by consistent genomic tracking, underpins the strong market consensus favoring no escalation in the near term.